Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study
Gail J. Roboz, Thomas Pabst, Ahmed Aribi, Joseph Brandwein et autres
0 citationsHaematologica
Argenx (Belgium)
Ghent · BE · company
373Publications signalées
16088Citations signalées
12Thèmes principaux
Principaux domaines
Myasthenia Gravis and ThymomaPeripheral Neuropathies and DisordersMonoclonal and Polyclonal Antibodies ResearchParkinson's Disease and Spinal DisordersAdrenal Hormones and DisordersAutoimmune Bullous Skin DiseasesCoagulation, Bradykinin, Polyphosphates, and AngioedemaPlatelet Disorders and TreatmentsMultiple Sclerosis Research StudiesCancer Treatment and PharmacologyHereditary Neurological DisordersGlycosylation and Glycoproteins Research
Évolution annuelle
Publications récentes
Investigating the Pharmacokinetics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administered with a Prefilled Syringe
Cassandra De Muynck, Jan Noukens, Koen Allosery, Clotilde Cettour-Rose et autres
0 citationsAdvances in Therapy
Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+)
Andreas Meisel, Carlo Antozzi, Ratna Bhavaraju-Sanka, Jan De Bleecker et autres
0 citationsFrontiers in Neurology
Effect of efgartigimod IV on immature platelet fraction in primary immune thrombocytopenia in the ADVANCE IV trial
Hanny Al‐Samkari, Filip Matthijssens, Kaichi Nishiwaki, Francesco Zaja et autres
0 citationsBritish Journal of Haematology
Impact of fatigue and disability on health-related quality of life in CIDP: Results from an international survey
Febe Brackx, C. Arvin-Berod, Sandra Paci, Johanna M. van Dongen et autres
0 citationsClinical Neurology and Neurosurgery
Assessing efgartigimod dosing patterns and Myasthenia Gravis Activities of Daily Living outcomes in clinical practice: results from a large patient support program database
Pushpa Narayanaswami, A Gordon Smith, Ratna Bhavaraju-Sanka, Cynthia Qi et autres
0 citationsFrontiers in Neurology
Industrialization of Bayesian decision-making for proof-of-commercial-concept study designs
Fan Wu, Pascal Minini, Gang Han, Bingzhi Zhang et autres
0 citationsJournal of Biopharmaceutical Statistics
Anti-C2–mediated complement inhibition prevents disease in a rat passive transfer model of myasthenia gravis
Britt Arets, Siyang Peng, Laura Bracke, Karen De Winter et autres
0 citationsJournal of Translational Autoimmunity
TNFAIP3/A20 dysfunction drives innate and sterile hyperinflammation
Karel Van Damme, Pieter Hertens, Dorine Sichien, Katrien Van der Borght et autres
0 citationsFrontiers in Immunology
Long‐Term Safety and Efficacy of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE / ADHERE + Trial Interim Analysis
Jeffrey A. Allen, Geoffrey Istas, Satoshi Kuwabara, Trevor Mole et autres
1 citationJournal of the Peripheral Nervous System
Assessing Efgartigimod (VYVGART™) Social Media Posts in Generalized Myasthenia Gravis to Understand Patient, Caregiver, and Health Care Professional Sentiments
Tom Hughes, Albert Whangbo, Swati Shukla, Aditya Batra et autres
0 citationsNeurology and Therapy
Engineering trispecific IL-2 receptor agonistic antibodies through geometry optimization for enhanced Treg targeting
Valentina Lykhopiy, Emilie Pollenus, Laurie Rangan, Michelle Stakenborg et autres
0 citationsNature Communications
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.